Targeted therapy plus hormone treatment for early breast cancer
Part of Cancer, Hormones & metabolism clinical trials.
This trial is testing a combination of two targeted drugs (pyrotinib and dalpiciclib) with standard hormone therapy for women with early-stage breast cancer that is HR+ and HER2-low. The goal is to see if this combination can shrink the tumor before surgery, so you can have a better outcome.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 75 years old, recently diagnosed with breast cancer and planning to have surgery.
- The cancer must be hormone-receptor positive (HR+) and HER2-low, meaning it has certain markers that guide treatment.
- The tumor must be larger than 5 cm or have spread to at least one lymph node, but it must not have spread to distant organs.
- You should be in generally good physical condition, as measured by a standard health score (ECOG 0–1).
- You must not have had prior cancer treatment (like chemotherapy or radiation) for any cancer, except for a few non-invasive types.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a “precision platform” approach—treatment before surgery—based on specific test results from your breast tumor. It may help determine whether the treatment plan works better for people with particular breast cancer subtypes and healthy organ function.
This trial compares two combination treatment plans given before breast surgery (neoadjuvant therapy) for ER-positive and HER2-positive stage II–III breast cancer. It aims to see which plan works better to shrink the tumor and improve outcomes.
This trial tests if adding a targeted drug (CDK4/6 inhibitor) to hormone therapy works better than hormone therapy alone for women with a certain type of breast cancer (HR+/HER2-). The study measures the activity of tumor cells (Ki-67) to help decide treatment.
This trial tests a combination of chemotherapy (docetaxel and carboplatin) plus two targeted drugs (Inetetamab and Pyrotinib) for people with locally advanced HER2-positive breast cancer that has not spread to other parts of the body. The goal is to see if this powerful combo can shrink the tumor before surgery or other treatments.
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) plus chemotherapy (capecitabine) before surgery for women with early-stage HER2-positive breast cancer. The goal is to shrink the tumor and improve treatment outcomes.
This trial tests a combination of three targeted drugs for a type of advanced breast cancer that is both ER-positive and HER2-positive. The goal is to see if adding these two new drugs to standard hormone therapy can help shrink or control the cancer.
Hear when a new Locally Advanced Breast Cancer (LABC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.